CA2371912C - Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation - Google Patents

Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation Download PDF

Info

Publication number
CA2371912C
CA2371912C CA2371912A CA2371912A CA2371912C CA 2371912 C CA2371912 C CA 2371912C CA 2371912 A CA2371912 A CA 2371912A CA 2371912 A CA2371912 A CA 2371912A CA 2371912 C CA2371912 C CA 2371912C
Authority
CA
Canada
Prior art keywords
paclitaxel
pharmacologically active
patients
abi
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2371912A
Other languages
English (en)
Other versions
CA2371912A1 (fr
Inventor
Neil P. Desai
Chunlin Tao
Andrew Yang
Leslie Louie
Zhiwen Yao
Patrick Soon-Shiong
Shlomo Magdassi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,642 external-priority patent/US6749868B1/en
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Priority to CA2684454A priority Critical patent/CA2684454A1/fr
Publication of CA2371912A1 publication Critical patent/CA2371912A1/fr
Application granted granted Critical
Publication of CA2371912C publication Critical patent/CA2371912C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions et des procédés convenant pour l'administration in vivo d'agents pharmacologiquement actifs essentiellement insolubles dans l'eau (tels que le médicament anticancéreux paclitaxel) dans lesquels un agent actif au plan pharmacologique est administré sous forme de particules en suspension enrobées d'une protéine (laquelle agit comme agent stabilisateur). En particulier, la protéine et l'agent pharmacologiquement actif présents dans un support dispersant biocompatible sont soumis à un cisaillement élevé en l'absence de tout tensioactif classique et en l'absence de matériau noyau polymère pour les particules. Le procédé selon l'invention permet d'obtenir des particules d'un diamètre inférieur au micron. L'utilisation d'une composition spécifique dans des conditions de préparation précises (adjonction d'un solvant polaire à la phase organique), et le choix raisonné de la phase organique appropriée et de la fraction de phase permet la production reproductible de nanoparticules exceptionnellement petites d'un diamètre inférieure à 200 nm qui peuvent être stérilisées par filtration. Le système de particules obtenu dans le cadre de l'invention peut être transformé en une poudre sèche redispersible comprenant des nanoparticules d'un médicament enrobé d'une protéine, insoluble dans l'eau, et d'une protéine libre à laquelle des molécules de l'agent pharmacologique sont liées. On obtient ainsi un système d'administration unique en son genre dans lequel un agent actif au plan pharmacologique est facilement biodisponible (sous forme de molécules liées à la protéine), et où une partie de l'agent est présente dans les particules sans aucune matrice polymère.
CA2371912A 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation Expired - Lifetime CA2371912C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2684454A CA2684454A1 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/316,642 1999-05-21
US09/316,642 US6749868B1 (en) 1993-02-22 1999-05-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US2000/013954 WO2000071079A2 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2684454A Division CA2684454A1 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Publications (2)

Publication Number Publication Date
CA2371912A1 CA2371912A1 (fr) 2000-11-30
CA2371912C true CA2371912C (fr) 2010-02-16

Family

ID=23229970

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2371912A Expired - Lifetime CA2371912C (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
CA2684454A Abandoned CA2684454A1 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2684454A Abandoned CA2684454A1 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1178786A4 (fr)
AU (3) AU784416B2 (fr)
CA (2) CA2371912C (fr)
HK (1) HK1045646A1 (fr)
WO (1) WO2000071079A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
RU2002113659A (ru) * 1999-10-27 2004-01-27 Бейкер Нортон Фармасьютикалз, Инк. (Us) Способ и композиции для перорального введения таксанов больным людям
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
WO2003032906A2 (fr) 2001-10-15 2003-04-24 Crititech, Inc. Compositions et methodes d'administration de medicaments faiblement hydrosolubles et methodes de traitement
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
NZ518997A (en) * 2002-05-16 2004-12-24 Interag Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent
SI21222A (sl) * 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
CN101102740A (zh) * 2005-01-07 2008-01-09 卫材R&D管理有限公司 药用组合物以及其制备方法
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP2008543842A (ja) * 2005-06-14 2008-12-04 バクスター インターナショナル インコーポレイテッド 薬物−薬物相互作用を最小にするための薬学的処方物
US7771751B2 (en) * 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EA015781B1 (ru) * 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
US8980323B2 (en) 2006-08-29 2015-03-17 Fujifilm Corporation Hydrophilic matrix containing poorly water-soluble compound and method for producing the same
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP3417859A1 (fr) 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticule comprenant de la rapamycine et de l'albumine en tant qu'agent anti-cancéreux
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
KR20100048751A (ko) * 2008-10-31 2010-05-11 주식회사 동성바이오레인 스프레이 가능한 캡슐화된 기능성 미립자 조성물과 그 제조방법
JP2012509921A (ja) 2008-11-27 2012-04-26 ビーエーエスエフ ソシエタス・ヨーロピア 固形製薬学的処方物中への付形剤としての表面活性タンパク質
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
CA3051495A1 (fr) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Utilisation de nanoparticules comprenant une taxane et une albumine pour le traitement de carcinome hepatocellulaire
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
EP3330283A3 (fr) 2012-03-16 2018-07-11 Albumedix A/S Variants d'albumine
CA2890766A1 (fr) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Variants d'albumine
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
CN104548116A (zh) * 2013-10-11 2015-04-29 程树海 一种稳定的蛋白质载药微粒系统制备方法
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
WO2018082758A1 (fr) 2016-11-04 2018-05-11 Aarhus Universitet Identification et traitement de tumeurs caractérisées par une surexpression du récepteur fc néonatal
DE102016125666A1 (de) 2016-12-23 2018-06-28 Michael Denck HSA-Galenik
WO2018200393A1 (fr) * 2017-04-24 2018-11-01 Zy Therapeutics Inc. Composition pharmaceutique pour l'administration in vivo, procédé de préparation d'un principe pharmacologiquement actif sensiblement insoluble dans l'eau
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin
CN114786654A (zh) * 2019-12-11 2022-07-22 密执安大学评议会 用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO1999000113A1 (fr) * 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Nouvelles formulations d'agents pharmacologiques, leurs procedes de preparation et d'utilisation

Also Published As

Publication number Publication date
AU784416B2 (en) 2006-03-30
WO2000071079A2 (fr) 2000-11-30
WO2000071079A3 (fr) 2008-03-27
EP1178786A4 (fr) 2006-03-01
EP1178786A1 (fr) 2002-02-13
CA2371912A1 (fr) 2000-11-30
CA2684454A1 (fr) 2000-11-18
AU2009217409A1 (en) 2009-10-08
HK1045646A1 (zh) 2002-12-06
AU2006202836B2 (en) 2009-10-08
AU5035900A (en) 2000-12-12
AU2006202836A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
AU2006202836B2 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CA2267498C (fr) Agents pharmaceutiquement actifs stabilises par proteine, procedes de preparation et procedes d'utilisation
US8137684B2 (en) Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20150104521A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070117863A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20080161382A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP2272504A2 (fr) Nouvelles formulations d'agents pharmacologiques, leurs procédés de préparation et d'utilisation
HK1119974A (en) Methods for the preparation of protein stabilized pharmacologically active agents
HK1119974B (en) Methods for the preparation of protein stabilized pharmacologically active agents
HK1024866B (en) Protein stabilized pharmacologically active agents and their use
HK1154511A (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
HK1152882A (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200519